The Miami Cancer Institute is one of the leading organizations in diversity amongst its clinical trials, and chief research officer Scott Lipkin, DPM, CIP, spoke on the present and future of diversity within the organization.
Janssen Pharmaceutical Companies recently announced the FDA granted breakthrough therapy designation to JNJ-61186372, an EGFR-MET bispecific antibody, for the treatment of metastatic non-small cell lung cancer with EGFR exon 20 mutations.
A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.
A recent study found that young women aged 18-39 diagnosed with breast cancer typically suffer through financial hardships regardless of outstanding life circumstances such as career and insurance coverage.
This study examined both cachexia-inducing factors and patients with various cancers to better understand the disparity between cancer types and developing cachexia.
A study published in Cancer suggests meeting the ACS guidelines for physical activity correlates with improved health-related quality of life and lower depression levels.
Kura Oncology’s leading drug candidate, tipifarnib, was granted fast track designation by the FDA to treat adults of T-cell lymphomas.
LUNGevity Foundation released a Lung Cancer Scorecard to examine how effectively (or ineffectively) states are addressing lung cancer.
The FDA recently granted priority review to Takeda’s supplemental new drug application for brigatinib to treat ALK-positive metastatic non-small cell lung cancer.
Roche recently announced the FDA accepted their supplemental biologics license application and granted priority review to atezolizumab for the treatment of non-small cell lung cancer.